Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.44 |
| ▸ | PDE5A | O76074 | 1/20 | 0.43 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | BCL2 | P10415 | 1/20 | 0.39 |
| ▸ | BECN1 | Q14457 | 1/20 | 0.39 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL520670 | 0.93 | ALDH1A1 (0.60) | ALDH1A1MAPTLMNANR1H2NR1H3 | |
| SCHEMBL7670172 | 0.91 | ALDH1A1 (0.58) | ALDH1A1MAPTLMNANR1H2NR1H3 | |
| SCHEMBL521741 | 0.87 | NR1H2 (0.48) | ALDH1A1MAPTLMNANR1H2NR1H3 | |
| SCHEMBL2809566 | 0.85 | NR1H2 (0.57) | NR1H2NR1H3ABHD6ROCK2 | |
| SCHEMBL16530352 | 0.84 | ALDH1A1 (0.42) | ALDH1A1MAPTPDE5ASMN1; SMN2HPGD | |
| SCHEMBL82172 | 0.84 | NR1H2 (0.57) | NR1H2NR1H3PDE5AABHD6ROCK2 | |
| SCHEMBL12988184 | 0.84 | NR1H2 (0.57) | NR1H2NR1H3PDE5AABHD6ROCK2 | |
| SCHEMBL521802 | 0.84 | NR1H2 (0.47) | ALDH1A1MAPTNR1H2NR1H3ABHD6 | |
| SCHEMBL83392 | 0.84 | MEN1 (0.48) | NR1H2NR1H3ABHD6ROCK2HPGD | |
| SCHEMBL25279026 | 0.82 | ALDH1A1 (0.54) | ALDH1A1MAPTLMNAPDE5APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | ALDH1A1 779/4885MAPT 3109/4885LMNA 3783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.